°®¶¹´«Ã½

°®¶¹´«Ã½. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the latest data on its in-house developed AMPA receptor antagonist Fycompa® (perampanel hydrate, “perampanel”) will be presented at the 69th American Epilepsy Society (AES) Annual Meeting to be held from December 4 to 8 in Philadelphia in the United States.

For this year's AES meeting, poster presentations will be given on 22 abstracts with highlights including additional and pooled analyses on the results of global Phase Ⅲ clinical studies on primary generalized tonic-clonic (PGTC) seizures in patients with generalized epilepsy (Study 332) and on partial-onset epilepsy (Study 304, Study 305, Study 306), as well as the results of a Phase Ⅲ clinical study on partial-onset epilepsy conducted in Asia including Japan. Furthermore, the overall results of Study 332¹, Study 304² and Study 306³ were published in the major scientific journal Neurology, while the overall results of Study 305⁴ were published in the specialist epilepsy journal Epilepsia.

Perampanel is a first-in-class antiepileptic drug (AED) discovered and developed by Eisai. With epileptic seizures being primarily mediated by the neurotransmitter glutamate, the agent is a highly selective, noncompetitive AMPA receptor antagonist that reduces neuronal hyperexcitation associated with seizures by targeting glutamate activity at postsynaptic AMPA receptors. Perampanel is approved in more than 45 countries including in Europe and North America, as well as countries in Asia such as Malaysia, Thailand, Philippines and South Korea, as an adjunctive treatment for partial-onset seizures (with or without secondarily generalized seizures) in patients with epilepsy aged 12 years and older, and has been launched in more than 25 countries around the world under the brand name Fycompa. Furthermore, perampanel was approved for an indication expansion regarding the adjunctive therapy of PGTC seizures in patients from 12 years of age with generalized epilepsy in the United States and Europe in June 2015. Meanwhile, Eisai submitted a regulatory application for perampanel in Japan covering both PGTC seizures and partial-onset seizures (with or without secondarily generalized seizures) based primarily on Study 332 and Study 335 in July 2015.

Epilepsy affects nearly 1 million people in Japan, 2.9 million people in the United States, 6 million people in Europe, and more than 60 million people worldwide. Furthermore, over half of the people with epilepsy worldwide are estimated to live in Asia.⁵ As approximately 30% of patients with epilepsy are unable to sufficiently control their seizures with currently available AEDs,⁶ this is a disease with significant unmet medical needs. Eisai considers epilepsy a therapeutic area of focus and by providing multiple treatment options in addition to perampanel as part of an extensive epilepsy product portfolio, Eisai seeks to make continued contributions to address the diverse needs of, as well as increasing the benefits provided to, patients with epilepsy and their families.